QUARTERLY REPORT

Q2 2024 — Form 10-Q

Q2 2024PDF · 38 pages375 KB
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended June 29, 2024 or
☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Commission File Number 1-8002
THERMO FISHER SCIENTIFIC INC.
(Exact name of Registrant as specified in its charter)
Delaware 	04-2209186
(State or other jurisdiction of incorporation or organization) 	(I.R.S. Employer Identification No.)
168 Third Avenue
Waltham, Massachusetts 02451
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (781) 622-1000
Securities registered pursuant to Section 12(b) of the Act:
Title of each class 	Trading Symbol(s) 	Name of each exchange on which registered
Common Stock, $1.00 par value 	TMO 	New York Stock Exchange
0.750% Notes due 2024 	TMO 24A 	New York Stock Exchange
0.125% Notes due 2025 	TMO 25B 	New York Stock Exchange
2.000% Notes due 2025 	TMO 25 	New York Stock Exchange
3.200% Notes due 2026 	TMO 26B 	New York Stock Exchange
1.400% Notes due 2026 	TMO 26A 	New York Stock Exchange
1.450% Notes due 2027 	TMO 27 	New York Stock Exchange
1.750% Notes due 2027 	TMO 27B 	New York Stock Exchange
0.500% Notes due 2028 	TMO 28A 	New York Stock Exchange
1.375% Notes due 2028 	TMO 28 	New York Stock Exchange
1.950% Notes due 2029 	TMO 29 	New York Stock Exchange
0.875% Notes due 2031 	TMO 31 	New York Stock Exchange
2.375% Notes due 2032 	TMO 32 	New York Stock Exchange
3.650% Notes due 2034 	TMO 34 	New York Stock Exchange
2.875% Notes due 2037 	TMO 37 	New York Stock Exchange
1.500% Notes due 2039 	TMO 39 	New York Stock Exchange
1.875% Notes due 2049 	TMO 49 	New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past
90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation
S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging
growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2
of the Exchange Act.
Large accelerated filer ☒ 	Accelerated filer ☐ 	Non-accelerated filer ☐
Smaller reporting company ☐ 	Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of June 29, 2024, the Registrant had 381,995,566 shares of Common Stock outstanding.

-- 1 of 38 --

THERMO FISHER SCIENTIFIC INC.
QUARTERLY REPORT ON FORM 10-Q
FOR THE QUARTER ENDED JUNE 29, 2024
TABLE OF CONTENTS
Page
PART I - FINANCIAL INFORMATION
Item 1. 	Financial Statements (Unaudited) 	3
Condensed Consolidated Balance Sheets 	3
Condensed Consolidated Statements of Income 	4
Condensed Consolidated Statements of Comprehensive Income 	5
Condensed Consolidated Statements of Cash Flows 	6
Condensed Consolidated Statements of Redeemable Noncontrolling Interest and Equity 	7
Notes to Condensed Consolidated Financial Statements 	9
Note 1. Nature of Operations and Summary of Significant Accounting Policies 	9
Note 2. Acquisitions 	10
Note 3. Revenues and Contract-related Balances 	11
Note 4. Business Segment and Geographical Information 	13
Note 5. Income Taxes 	14
Note 6. Earnings per Share 	15
Note 7. Debt and Other Financing Arrangements 	15
Note 8. Commitments and Contingencies 	17
Note 9. Comprehensive Income/(Loss) and Shareholders' Equity 	18
Note 10. Fair Value Measurements and Fair Value of Financial Instruments 	19
Note 11. Supplemental Cash Flow Information 	21
Note 12. Restructuring and Other Costs 	22
Item 2. 	Management’s Discussion and Analysis of Financial Condition and Results of Operations 	23
Item 3. 	Quantitative and Qualitative Disclosures About Market Risk 	31
Item 4. 	Controls and Procedures 	31
PART II - OTHER INFORMATION
Item 1. 	Legal Proceedings 	32
Item 1A. 	Risk Factors 	32
Item 2. 	Unregistered Sales of Equity Securities and Use of Proceeds 	32
Item 5. 	Other Information 	32
Item 6. 	Exhibits 	33
2

-- 2 of 38 --

THERMO FISHER SCIENTIFIC INC.
PART I FINANCIAL INFORMATION
Item 1. Financial Statements
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
June 29, 	December 31,
(In millions except share and per share amounts) 	2024 	2023
Assets
Current assets:
Cash and cash equivalents 	$ 	7,073 	$ 	8,077
Short-term investments 	1,750 	3
Accounts receivable, less allowances of $202 and $193 	7,943 	8,221
Inventories 	5,198 	5,088
Contract assets, net 	1,487 	1,443
Other current assets 	2,025 	1,757
Total current assets 	25,476 	24,589
Property, plant and equipment, net 	9,282 	9,448
Acquisition-related intangible assets, net 	15,519 	16,670
Other assets 	4,377 	3,999
Goodwill 	43,843 	44,020
Total assets 	$ 	98,496 	$ 	98,726
Liabilities, redeemable noncontrolling interest and equity
Current liabilities:
Short-term obligations and current maturities of long-term obligations 	$ 	5,121 	$ 	3,609
Accounts payable 	2,547 	2,872
Accrued payroll and employee benefits 	1,495 	1,596
Contract liabilities 	2,591 	2,689
Other accrued expenses 	3,019 	3,246
Total current liabilities 	14,772 	14,012
Deferred income taxes 	1,516 	1,922
Other long-term liabilities 	4,391 	4,642
Long-term obligations 	30,284 	31,308
Redeemable noncontrolling interest 	115 	118
Equity:
Thermo Fisher Scientific Inc. shareholders’ equity:
Preferred stock, $100 par value, 50,000 shares authorized; none issued 	— 	—
Common stock, $1 par value, 1,200,000,000 shares authorized; 443,105,658 and 442,188,634 shares issued 	443 	442
Capital in excess of par value 	17,649 	17,286
Retained earnings 	49,940 	47,364
Treasury stock at cost, 61,110,092 and 55,541,290 shares 	(18,187) 	(15,133)
Accumulated other comprehensive income/(loss) 	(2,413) 	(3,224)
Total Thermo Fisher Scientific Inc. shareholders’ equity 	47,432 	46,735
Noncontrolling interests 	(12) 	(11)
Total equity 	47,419 	46,724
Total liabilities, redeemable noncontrolling interest and equity 	$ 	98,496 	$ 	98,726
The accompanying notes are an integral part of these condensed consolidated financial statements.
3

-- 3 of 38 --

THERMO FISHER SCIENTIFIC INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)
Three months ended 	Six months ended
June 29, 	July 1, 	June 29, 	July 1,
(In millions except per share amounts) 	2024 	2023 	2024 	2023
Revenues
Product revenues 	$ 	6,163 $ 	6,271 $ 	12,118 $ 	12,675
Service revenues 	4,378 	4,416 	8,768 	8,722
Total revenues 	10,541 	10,687 	20,886 	21,397
Costs and operating expenses:
Cost of product revenues 	3,080 	3,278 	6,019 	6,615
Cost of service revenues 	3,114 	3,158 	6,315 	6,391
Selling, general and administrative expenses 	2,111 	2,145 	4,293 	4,264
Research and development expenses 	339 	345 	670 	691
Restructuring and other costs 	77 	183 	106 	295
Total costs and operating expenses 	8,722 	9,109 	17,404 	18,256
Operating income 	1,820 	1,578 	3,483 	3,141
Interest income 	295 	178 	574 	324
Interest expense 	(354) 	(326) 	(717) 	(626)
Other income/(expense) 	5 	— 	14 	(46)
Income before income taxes 	1,765 	1,430 	3,354 	2,793
Provision for income taxes 	(128) 	(52) 	(408) 	(98)
Equity in earnings/(losses) of unconsolidated entities 	(84) 	(16) 	(61) 	(41)
Net income 	1,553 	1,362 	2,885 	2,654
Less: net income/(losses) attributable to noncontrolling interests and redeemable
noncontrolling interest 	6 	1 	9 	4
Net income attributable to Thermo Fisher Scientific Inc. 	$ 	1,548 $ 	1,361 $ 	2,875 $ 	2,650
Earnings per share attributable to Thermo Fisher Scientific Inc.
Basic 	$ 	4.05 $ 	3.53 $ 	7.53 $ 	6.86
Diluted 	$ 	4.04 $ 	3.51 $ 	7.50 $ 	6.83
Weighted average shares
Basic 	382 	386 	382 	386
Diluted 	383 	388 	383 	388
The accompanying notes are an integral part of these condensed consolidated financial statements.
4

-- 4 of 38 --

THERMO FISHER SCIENTIFIC INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(Unaudited)
Three months ended 	Six months ended
June 29, 	July 1, 	June 29, 	July 1,
(In millions) 	2024 	2023 	2024 	2023
Comprehensive income
Net income 	$ 	1,553 $ 	1,362 $ 	2,885 $ 	2,654
Other comprehensive income/(loss):
Currency translation adjustment:
Currency translation adjustment (net of tax provision (benefit) of $88, $0, $255
and $(36)) 	346 	125 	802 	169
Unrealized gains/(losses) on available-for-sale debt securities
Unrealized holding losses arising during the period (net of tax (provision) benefit of
$0, $0, $0 and $0) 	— 	— 	(1) 	—
Unrealized gains/(losses) on hedging instruments:
Reclassification adjustment for losses included in net income (net of tax
(provision) benefit of $0, $0, $0 and $1) 	1 	1 	1 	4
Pension and other postretirement benefit liability adjustments:
Pension and other postretirement benefit liability adjustments arising during the
period (net of tax (provision) benefit of $0, $1, $0 and $0) 	— 	(1) 	1 	—
Amortization of net loss included in net periodic pension cost (net of tax
(provision) benefit of $0, $0, $0 and $0) 	1 	(2) 	1 	(2)
Total other comprehensive income/(loss) 	348 	123 	805 	171
Comprehensive income 	1,901 	1,485 	3,689 	2,825
Less: comprehensive income/(loss) attributable to noncontrolling interests and redeemable
noncontrolling interest 	3 	(6) 	3 	—
Comprehensive income attributable to Thermo Fisher Scientific Inc. 	$ 	1,899 $ 	1,491 $ 	3,686 $ 	2,825
The accompanying notes are an integral part of these condensed consolidated financial statements.
5

-- 5 of 38 --

THERMO FISHER SCIENTIFIC INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
Six months ended
June 29, 	July 1,
(In millions) 	2024 	2023
Operating activities
Net income 	$ 	2,885 	$ 	2,654
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation of property, plant and equipment 	562 	523
Amortization of acquisition-related intangible assets 	1,065 	1,191
Change in deferred income taxes 	(607) 	(328)
Stock-based compensation 	154 	150
Other non-cash expenses, net 	157 	330
Changes in assets and liabilities, excluding the effects of acquisitions 	(1,003) 	(2,251)
Net cash provided by operating activities 	3,211 	2,269
Investing activities
Purchases of property, plant and equipment 	(648) 	(742)
Proceeds from sale of property, plant and equipment 	20 	10
Proceeds from cross-currency interest rate swap interest settlements 	111 	35
Acquisitions, net of cash acquired 	— 	(2,751)
Purchases of investments 	(1,778) 	(188)
Other investing activities, net 	12 	51
Net cash used in investing activities 	(2,283) 	(3,585)
Financing activities
Net proceeds from issuance of debt 	1,204 	—
Repayment of debt 	— 	(1,000)
Proceeds from issuance of commercial paper 	— 	1,620
Repayments of commercial paper 	— 	(1,441)
Purchases of company common stock 	(3,000) 	(3,000)
Dividends paid 	(284) 	(252)
Other financing activities, net 	145 	24
Net cash used in financing activities 	(1,936) 	(4,049)
Exchange rate effect on cash 	7 	(19)
Decrease in cash, cash equivalents and restricted cash 	(1,000) 	(5,384)
Cash, cash equivalents and restricted cash at beginning of period 	8,097 	8,537
Cash, cash equivalents and restricted cash at end of period 	$ 	7,097 	$ 	3,153
The accompanying notes are an integral part of these condensed consolidated financial statements.
6

-- 6 of 38 --

THERMO FISHER SCIENTIFIC INC.
CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTEREST AND EQUITY
(Unaudited)
Redeemable
Noncontrolling
Interest
Common Stock 	Capital in
Excess of
Par Value
Retained
Earnings
Treasury Stock
Accumulated
Other
Comprehensive
Items
Total
Thermo Fisher
Scientific Inc.
Shareholders’
Equity
Noncontrolling
Interests Total Equity	(In millions) 	Shares 	Amount 	Shares 	Amount
Three months ended June 29, 2024
Balance at March 30, 2024 	$ 	119 	443 $ 	443 $ 17,482 $ 48,542 	61 $ (18,186) $ 	(2,764) $ 	45,516 $ 	(12) $ 45,504
Issuance of shares under
employees' and directors' stock
plans 	— 	— 	— 	83 	— 	— 	(2) 	— 	81 	— 	81
Stock-based compensation 	— 	— 	— 	84 	— 	— 	— 	— 	84 	— 	84
Dividends declared ($0.39 per
share) 	— 	— 	— 	— 	(149) 	— 	— 	— 	(149) 	— 	(149)
Net income/(loss) 	6 	— 	— 	— 	1,548 	— 	— 	— 	1,548 	— 	1,548
Other comprehensive items 	(3) 	— 	— 	— 	— 	— 	— 	351 	351 	— 	351
Contributions from (distributions
to) noncontrolling interests 	(7) 	— 	— 	— 	— 	— 	— 	— 	— 	— 	—
Excise tax from stock repurchases 	— 	— 	— 	— 	— 	— 	1 	— 	1 	— 	1
Balance at June 29, 2024 	$ 	115 	443 $ 	443 $ 17,649 $ 49,940 	61 $ (18,187) $ 	(2,413) $ 	47,432 $ 	(12) $ 47,419
Three months ended July 1, 2023
Balance at April 1, 2023 	$ 	123 	441 $ 	441 $ 16,889 $ 43,064 	55 $ (15,083) $ 	(3,054) $ 	42,257 $ 	53 $ 42,310
Issuance of shares under
employees' and directors' stock
plans 	— 	— 	— 	67 	— 	— 	(2) 	— 	65 	— 	65
Stock-based compensation 	— 	— 	— 	74 	— 	— 	— 	— 	74 	— 	74
Dividends declared ($0.35 per
share) 	— 	— 	— 	— 	(136) 	— 	— 	— 	(136) 	— 	(136)
Net income/(loss) 	4 	— 	— 	— 	1,361 	— 	— 	— 	1,361 	(3) 	1,358
Other comprehensive items 	(7) 	— 	— 	— 	— 	— 	— 	130 	130 	— 	130
Contributions from (distributions
to) noncontrolling interests 	(7) 	— 	— 	— 	— 	— 	— 	— 	— 	— 	—
Excise tax from stock repurchases 	— 	— 	— 	— 	— 	— 	1 	— 	1 	— 	1
Balance at July 1, 2023 	$ 	113 	441 $ 	441 $ 17,030 $ 44,289 	55 $ (15,084) $ 	(2,924) $ 	43,752 $ 	50 $ 43,802
The accompanying notes are an integral part of these condensed consolidated financial statements.
7

-- 7 of 38 --

THERMO FISHER SCIENTIFIC INC.
CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTEREST AND EQUITY (Continued)
(Unaudited)
Redeemable
Noncontrolling
Interest
Common Stock 	Capital in
Excess of
Par Value
Retained
Earnings
Treasury Stock
Accumulated
Other
Comprehensive
Items
Total
Thermo Fisher
Scientific Inc.
Shareholders’
Equity
Noncontrolling
Interests Total Equity	(In millions) 	Shares 	Amount 	Shares 	Amount
Six months ended June 29, 2024
Balance at December 31, 2023 	$ 	118 	442 $ 	442 $ 17,286 $ 47,364 	56 $ (15,133) $ 	(3,224) $ 	46,735 $ 	(11) $ 46,724
Issuance of shares under stock
plans 	— 	1 	1 	209 	— 	— 	(26) 	— 	184 	— 	184
Stock-based compensation 	— 	— 	— 	154 	— 	— 	— 	— 	154 	— 	154
Purchases of company common
stock 	— 	— 	— 	— 	— 	6 	(3,000) 	— 	(3,000) 	— 	(3,000)
Dividends declared ($0.78 per
share) 	— 	— 	— 	— 	(298) 	— 	— 	— 	(298) 	— 	(298)
Net income/(loss) 	10 	— 	— 	— 	2,875 	— 	— 	— 	2,875 	(1) 	2,874
Other comprehensive items 	(6) 	— 	— 	— 	— 	— 	— 	811 	811 	— 	811
Contributions from (distributions
to) noncontrolling interest 	(7) 	— 	— 	— 	— 	— 	— 	— 	— 	(1) 	(1)
Excise tax from stock repurchases 	— 	— 	— 	— 	— 	— 	(28) 	— 	(28) 	— 	(28)
Balance at June 29, 2024 	$ 	115 	443 $ 	443 $ 17,649 $ 49,940 	61 $ (18,187) $ 	(2,413) $ 	47,432 $ 	(12) $ 47,419
Six months ended July 1, 2023
Balance at December 31, 2022 	$ 	116 	441 $ 	441 $ 16,743 $ 41,910 	50 $ (12,017) $ 	(3,099) $ 	43,978 $ 	54 $ 44,032
Issuance of shares under stock
plans 	— 	— 	— 	137 	— 	— 	(38) 	— 	99 	— 	99
Stock-based compensation 	— 	— 	— 	150 	— 	— 	— 	— 	150 	— 	150
Purchases of company common
stock 	— 	— 	— 	— 	— 	5 	(3,000) 	— 	(3,000) 	— 	(3,000)
Dividends declared ($0.70 per
share) 	— 	— 	— 	— 	(271) 	— 	— 	— 	(271) 	— 	(271)
Net income/(loss) 	8 	— 	— 	— 	2,650 	— 	— 	— 	2,650 	(4) 	2,646
Other comprehensive items 	(4) 	— 	— 	— 	— 	— 	— 	175 	175 	— 	175
Contributions from (distributions
to) noncontrolling interest 	(7) 	— 	— 	— 	— 	— 	— 	— 	— 	— 	—
Excise tax from stock repurchases 	— 	— 	— 	— 	— 	— 	(29) 	— 	(29) 	— 	(29)
Balance at July 1, 2023 	$ 	113 	441 $ 	441 $ 17,030 $ 44,289 	55 $ (15,084) $ 	(2,924) $ 	43,752 $ 	50 $ 43,802
The accompanying notes are an integral part of these condensed consolidated financial statements.
8

-- 8 of 38 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Note 1. Nature of Operations and Summary of Significant Accounting Policies
Nature of Operations
Thermo Fisher Scientific Inc. (the company or Thermo Fisher) enables customers to make the world healthier, cleaner and safer by helping them accelerate life
sciences research, solve complex analytical challenges, increase laboratory productivity, and improve patient health through diagnostics and the development and
manufacture of life-changing therapies. Markets served include pharmaceutical and biotech, academic and government, industrial and applied, as well as healthcare
and diagnostics.
Interim Financial Statements
The interim condensed consolidated financial statements presented herein have been prepared by the company, are unaudited and, in the opinion of management,
reflect all adjustments of a normal recurring nature necessary for a fair statement of the financial position at June 29, 2024, the results of operations for the three-
and six-month periods ended June 29, 2024 and July 1, 2023, and the cash flows for the six-month periods ended June 29, 2024 and July 1, 2023. Interim results are
not necessarily indicative of results for a full year.
The condensed consolidated balance sheet presented as of December 31, 2023 has been derived from the audited consolidated financial statements as of that date.
The condensed consolidated financial statements and notes are presented as permitted by Form 10-Q and do not contain all information that is included in the
annual financial statements and notes thereto of the company. The condensed consolidated financial statements and notes included in this report should be read in
conjunction with the 2023 financial statements and notes included in the company’s Annual Report on Form 10-K filed with the Securities and Exchange
Commission (SEC). Certain reclassifications of prior year amounts have been made to conform to the current year presentation.
Note 1 to the consolidated financial statements for 2023 describes the significant accounting estimates and policies used in preparation of the consolidated financial
statements. There have been no material changes in the company’s significant accounting policies during the six months ended June 29, 2024.
Amounts and percentages reported within these condensed consolidated financial statements are presented and calculated based on underlying unrounded amounts.
As a result, the sum of components may not equal corresponding totals due to rounding.
Inventories
The components of inventories are as follows:
(In millions) 	June 29, 2024 	December 31, 2023
Raw materials 	$ 	1,974 	$ 	2,057
Work in process 	825 	705
Finished goods 	2,399 	2,326
Inventories 	$ 	5,198 	$ 	5,088
Use of Estimates
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of
revenues and expenses during the reporting period.
The company’s estimates include, among others, asset reserve requirements as well as the amounts of future cash flows associated with certain assets and
businesses that are used in assessing the risk of impairment. Actual results could differ from those estimates.
Recent Accounting Pronouncements
The following table provides a description of recent accounting pronouncements adopted and those standards not yet adopted with potential for a material impact on
the company's financial statements or disclosures.
9

-- 9 of 38 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Standard 	Description 	Required adoption timing and approach Impact of adoption or other significant matters
Standards recently adopted
ASU No. 2022-04, Liabilities-
Supplier Finance Programs
(Subtopic 405-50): Disclosure of
Supplier Finance Program
Obligations
New guidance to disclose information about
supplier finance programs. Among other
things, the new guidance requires expanded
disclosure about key program terms, payment
terms, and amounts outstanding for obligations
under supplier finance programs for each
period presented.
Some aspects adopted in 2023 using a
retrospective method and will adopt
other aspects in 2024 annual report
using a prospective method
Not material
Standards not yet adopted
ASU No. 2023-07, Segment
Reporting (Topic 280): Improving
Reportable Segment Disclosures
Among other things, new guidance to disclose
significant segment expenses and other items
by reportable segment as well as information
about the chief operating decision maker.
2024 annual report and interim periods
thereafter using a retrospective method
Will increase disclosures in Note 4
ASU No. 2023-09, Income Taxes
(Topic 740): Improvements to
Income Tax Disclosures
Among other things, new guidance to disclose
additional information about the tax rate
reconciliation and income taxes paid.
2025 annual report and interim periods
thereafter using a prospective or
retrospective method
Will increase disclosures in Note 5
Note 2. Acquisitions
The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill,
primarily due to expectations of the synergies that will be realized by combining the businesses and the benefits that will be gained from the assembled workforces.
These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of
the acquired businesses’ products and services; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company
products and services.
Acquisitions have been accounted for using the acquisition method of accounting, and the acquired companies’ results have been included in the accompanying
financial statements from their respective dates of acquisition.
2024
On July 10, 2024, the company acquired, within the Life Sciences Solutions segment, Olink Holding AB (publ), a Swedish-based provider of next-generation
proteomics solutions. The acquisition enhances the segment’s capabilities in the high-growth proteomics market with the addition of highly differentiated solutions.
It also complements the existing life sciences and mass spectrometry offerings, accelerating protein biomarker discovery and providing strong synergy
opportunities. The goodwill recorded as a result of this business combination is not expected to be tax deductible.
The components of the preliminary purchase price and net assets acquired are as follows:
(In billions) 	Olink
Purchase price
Cash paid 	$ 	3.19
Fair value of noncontrolling interest 	0.06
Cash acquired 	(0.04)
$ 	3.21
Net assets acquired
Definite-lived intangible assets 	$ 	0.99
Goodwill 	2.28
Net tangible assets 	0.13
Deferred tax assets (liabilities) 	(0.19)
$ 	3.21
The weighted-average amortization period for definite-lived intangible assets is 18 years.
10

-- 10 of 38 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
The preliminary allocation of the purchase price for the acquisition of Olink is based on the estimates of the fair value of the net assets acquired and is subject to
adjustment upon finalization, largely with respect to acquired intangible assets and the related deferred taxes. Measurements of these items inherently require
significant estimates and assumptions.
2023
On January 3, 2023, the company acquired, within the Specialty Diagnostics segment, The Binding Site Group, a U.K.-based provider of specialty diagnostic assays
and instruments to improve the diagnosis and management of blood cancers and immune system disorders. The acquisition expands the segment’s portfolio with the
addition of pioneering innovation in diagnostics and monitoring for multiple myeloma. The goodwill recorded as a result of this business combination is not tax
deductible.
On August 14, 2023, the company acquired, within the Laboratory Products and Biopharma Services segment, CorEvitas, LLC, a U.S.-based provider of
regulatory-grade, real-world evidence for approved medical treatments and therapies. The acquisition expands the segment’s portfolio with the addition of highly
complementary real-world evidence solutions to enhance decision-making as well as the time and cost of drug development. The goodwill recorded as a result of
this business combination is not tax deductible.
The components of the purchase price and net assets acquired are as follows:
(In millions) 	The Binding Site 	CorEvitas
Purchase price
Cash paid 	$ 	2,412 $ 	730
Debt settled 	307 	184
Cash acquired 	(20) 	(4)
$ 	2,699 $ 	910
Net assets acquired
Definite-lived intangible assets:
Customer relationships 	$ 	868 $ 	260
Product technology 	162 	47
Tradenames 	42 	—
Backlog 	— 	46
Goodwill 	1,741 	627
Net tangible assets 	174 	(2)
Deferred tax assets (liabilities) 	(288) 	(68)
$ 	2,699 $ 	910
In addition, in 2023, the company acquired, within the Analytical Instruments segment, a U.S.-based developer of Raman-based spectroscopy solutions for in-line
measurement.
The weighted-average amortization periods for definite-lived intangible assets acquired in 2023 are 18 years for customer relationships, 14 years for product
technology, 15 years for tradenames, and 13 years for backlog. The weighted average amortization period for all definite-lived intangible assets acquired in 2023 is
17 years.
Note 3. Revenues and Contract-related Balances
Disaggregated Revenues
Revenues by type are as follows:
Three months ended 	Six months ended
(In millions) 	June 29, 2024 	July 1, 2023 	June 29, 2024 	July 1, 2023
Revenues
Consumables 	$ 	4,363 	$ 	4,433 	$ 	8,690 	$ 	8,939
Instruments 	1,800 	1,838 	3,428 	3,736
Services 	4,378 	4,416 	8,768 	8,722
Consolidated revenues 	$ 	10,541 	$ 	10,687 	$ 	20,886 	$ 	21,397
11

-- 11 of 38 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Revenues by geographic region based on customer location are as follows:
Three months ended 	Six months ended
(In millions) 	June 29, 2024 	July 1, 2023 	June 29, 2024 	July 1, 2023
Revenues
North America 	$ 	5,529 	$ 	5,714 	$ 	11,048 	$ 	11,492
Europe 	2,663 	2,654 	5,282 	5,255
Asia-Pacific 	1,971 	1,902 	3,831 	3,888
Other regions 	379 	417 	725 	762
Consolidated revenues 	$ 	10,541 	$ 	10,687 	$ 	20,886 	$ 	21,397
Each reportable segment earns revenues from consumables, instruments and services in North America, Europe, Asia-Pacific and other regions. See Note 4 for
revenues by reportable segment and other geographic data.
Remaining Performance Obligations
The aggregate amount of the transaction price allocated to the remaining performance obligations for all open customer contracts as of June 29, 2024 was $25.93
billion. The company will recognize revenues for these performance obligations as they are satisfied, approximately 52% of which is expected to occur within the
next twelve months. Amounts expected to occur thereafter generally relate to contract manufacturing, clinical research and extended warranty service agreements,
which typically have durations of three to five years.
Contract-related Balances
Noncurrent contract assets and noncurrent contract liabilities are included within other assets and other long-term liabilities in the accompanying balance sheet,
respectively. Contract asset and liability balances are as follows:
(In millions) 	June 29, 2024 	December 31, 2023
Current contract assets, net 	$ 	1,487 	$ 	1,443
Noncurrent contract assets, net 	7 	4
Current contract liabilities 	2,591 	2,689
Noncurrent contract liabilities 	1,455 	1,499
In the three and six months ended June 29, 2024, the company recognized revenues of $0.67 billion and $2.00 billion, respectively, that were included in the
contract liabilities balance at December 31, 2023. In the three and six months ended July 1, 2023, the company recognized revenues of $0.68 billion and $1.98
billion, respectively, that were included in the contract liabilities balance at December 31, 2022.
12

-- 12 of 38 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Note 4. Business Segment and Geographical Information
Business Segment Information
Three months ended 	Six months ended
June 29, 	July 1, 	June 29, 	July 1,
(In millions) 	2024 	2023 	2024 	2023
Revenues
Life Sciences Solutions 	$ 	2,355 	$ 	2,463 	$ 	4,640 	$ 	5,075
Analytical Instruments 	1,782 	1,749 	3,469 	3,472
Specialty Diagnostics 	1,117 	1,109 	2,227 	2,217
Laboratory Products and Biopharma Services 	5,758 	5,831 	11,480 	11,594
Eliminations 	(470) 	(465) 	(930) 	(961)
Consolidated revenues 	10,541 	10,687 	20,886 	21,397
Segment Income
Life Sciences Solutions 	865 	817 	1,705 	1,653
Analytical Instruments 	439 	432 	838 	853
Specialty Diagnostics 	299 	297 	593 	577
Laboratory Products and Biopharma Services 	745 	824 	1,489 	1,617
Subtotal reportable segments 	2,347 	2,370 	4,625 	4,700
Cost of revenues adjustments 	(1) 	(18) 	(17) 	(59)
Selling, general and administrative expenses adjustments 	64 	(6) 	45 	(14)
Restructuring and other costs 	(77) 	(183) 	(106) 	(295)
Amortization of acquisition-related intangible assets 	(513) 	(585) 	(1,065) 	(1,191)
Consolidated operating income 	1,820 	1,578 	3,483 	3,141
Interest income 	295 	178 	574 	324
Interest expense 	(354) 	(326) 	(717) 	(626)
Other income/(expense) 	5 	— 	14 	(46)
Consolidated income before taxes 	$ 	1,765 	$ 	1,430 	$ 	3,354 	$ 	2,793
Cost of revenues adjustments included in the above table consist of charges for the sale of inventories revalued at the date of acquisition, inventory write-downs
associated with large-scale abandonment of product lines, and accelerated depreciation on manufacturing assets to be abandoned due to facility consolidations.
Selling, general and administrative expenses adjustments included in the above table consist of third-party transaction/integration costs related to recent
acquisitions, and charges/credits for changes in estimates of contingent acquisition consideration.
Geographical Information
Revenues by country based on customer location are as follows:
Three months ended 	Six months ended
(In millions) 	June 29, 2024 	July 1, 2023 	June 29, 2024 	July 1, 2023
Revenues
United States 	$ 	5,347 	$ 	5,531 	$ 	10,669 	$ 	11,118
Other 	5,194 	5,156 	10,217 	10,279
Consolidated revenues 	$ 	10,541 	$ 	10,687 	$ 	20,886 	$ 	21,397
13

-- 13 of 38 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Note 5. Income Taxes
The provision for income taxes in the accompanying statements of income differs from the provision calculated by applying the statutory federal income tax rate to
income before provision for income taxes due to the following:
Six months ended
(In millions) 	June 29, 2024 	July 1, 2023
Statutory federal income tax rate 	21 % 	21 %
Provision for income taxes at statutory rate 	$ 	704 	$ 	587
Increases (decreases) resulting from:
Foreign rate differential 	(76) 	(125)
Income tax credits 	(141) 	(136)
Global intangible low-taxed income 	25 	46
Foreign-derived intangible income 	(47) 	(55)
Excess tax benefits from stock options and restricted stock units 	(45) 	(37)
Provision for (reversal of) tax reserves, net 	195 	8
Intra-entity transfers 	(102) 	(144)
Foreign exchange loss on inter-company debt refinancing 	— 	(112)
Provision for (reversal of) valuation allowances, net 	(67) 	66
Withholding taxes 	9 	12
Tax return reassessments and settlements 	(35) 	(38)
State income taxes, net of federal tax 	39 	53
Equity method investments 	(45) 	(6)
Other, net 	(4) 	(21)
Provision for income taxes 	$ 	408 	$ 	98
During the first quarter of 2024, the company recorded a tax reserve and associated interest of $240 million related to the potential settlement of international tax
audits for tax years 2009 through 2016. During the second quarter of 2024, the company recorded a benefit of $183 million, primarily in jurisdictions where the
deferred tax assets are now expected to be realized due to forecasted income.
The company has operations and a taxable presence in approximately 70 countries outside the U.S. The company's effective income tax rate differs from the U.S.
federal statutory rate each year due to certain operations that are subject to tax incentives, state and local taxes, and foreign taxes that are different than the U.S.
federal statutory rate.
Unrecognized Tax Benefits
As of June 29, 2024 the company had $0.70 billion of unrecognized tax benefits substantially all of which, if recognized, would reduce the effective tax rate. A
reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows:
(In millions) 	2024
Balance at beginning of year 	$ 	540
Additions for tax positions of current year 	9
Additions for tax positions of prior years 	199
Reductions for tax positions of prior years 	(46)
Balance at end of period 	$ 	702
14

-- 14 of 38 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Note 6. Earnings per Share
Three months ended 	Six months ended
June 29, 	July 1, 	June 29, 	July 1,
(In millions except per share amounts) 	2024 	2023 	2024 	2023
Net income attributable to Thermo Fisher Scientific Inc. 	$ 	1,548 $ 	1,361 $ 	2,875 $ 	2,650
Basic weighted average shares 	382 	386 	382 	386
Plus effect of: stock options and restricted stock units 	1 	2 	1 	2
Diluted weighted average shares 	383 	388 	383 	388
Basic earnings per share 	$ 	4.05 $ 	3.53 $ 	7.53 $ 	6.86
Diluted earnings per share 	$ 	4.04 $ 	3.51 $ 	7.50 $ 	6.83
Antidilutive stock options excluded from diluted weighted average shares 	2 	2 	2 	2
Note 7. Debt and Other Financing Arrangements
Effective interest rate at
June 29, 	June 29, 	December 31,
(Dollars in millions) 	2024 	2024 	2023
0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated) 	0.92 % 	1,071 	1,104
1.215% 3-Year Senior Notes, Due 10/18/2024 	1.42 % 	2,500 	2,500
0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated) 	0.40 % 	857 	883
2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated) 	2.09 % 	686 	706
0.853% 3-Year Senior Notes, Due 10/20/2025 (Japanese yen-denominated) 	1.05 % 	139 	158
0.000% 4-Year Senior Notes, Due 11/18/2025 (euro-denominated) 	0.15 % 	589 	607
3.20% 3-Year Senior Notes, Due 1/21/2026 (euro-denominated) 	3.38 % 	536 	552
1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated) 	1.52 % 	750 	773
4.953% 3-Year Senior Notes, Due 8/10/2026 	5.19 % 	600 	600
5.000% 3-Year Senior Notes, Due 12/5/2026 	5.26 % 	1,000 	1,000
1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated) 	1.65 % 	536 	552
1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated) 	1.96 % 	643 	662
1.054% 5-Year Senior Notes, Due 10/20/2027 (Japanese yen-denominated) 	1.18 % 	180 	205
4.80% 5-Year Senior Notes, Due 11/21/2027 	5.00 % 	600 	600
0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated) 	0.76 % 	857 	883
1.6525% 4-Year Senior Notes, Due 3/7/2028 (Swiss franc-denominated) 	1.80 % 	367 	—
0.77% 5-Year Senior Notes, Due 9/6/2028 (Japanese yen-denominated) 	0.90 % 	180 	206
1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated) 	1.46 % 	643 	662
1.75% 7-Year Senior Notes, Due 10/15/2028 	1.89 % 	700 	700
5.000% 5-Year Senior Notes, Due 1/31/2029 	5.24 % 	1,000 	1,000
1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated) 	2.07 % 	750 	773
2.60% 10-Year Senior Notes, Due 10/1/2029 	2.74 % 	900 	900
1.279% 7-Year Senior Notes, Due 10/19/2029 (Japanese yen-denominated) 	1.44 % 	29 	33
4.977% 7-Year Senior Notes, Due 8/10/2030 	5.12 % 	750 	750
0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated) 	0.88 % 	1,875 	1,932
0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated) 	1.13 % 	964 	993
2.00% 10-Year Senior Notes, Due 10/15/2031 	2.23 % 	1,200 	1,200
1.8401% 8-Year Senior Notes, Due 3/8/2032 (Swiss franc-denominated) 	1.92 % 	462 	—
15

-- 15 of 38 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Effective interest rate at
June 29, 	June 29, 	December 31,
(Dollars in millions) 	2024 	2024 	2023
2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated) 	2.54 % 	643 	662
1.49% 10-Year Senior Notes, Due 10/20/2032 (Japanese yen-denominated) 	1.60 % 	39 	45
4.95% 10-Year Senior Notes, Due 11/21/2032 	5.09 % 	600 	600
5.086% 10-Year Senior Notes, Due 8/10/2033 	5.20 % 	1,000 	1,000
1.125% 12-Year Senior Notes, Due 10/18/2033 (euro-denominated) 	1.20 % 	1,607 	1,656
5.200% 10-Year Senior Notes, Due 1/31/2034 	5.34 % 	500 	500
3.65% 12-Year Senior Notes, Due 11/21/2034 (euro-denominated) 	3.76 % 	803 	828
1.50% 12-Year Senior Notes, Due 9/6/2035 (Japanese yen-denominated) 	1.58 % 	134 	152
2.0375% 12-Year Senior Notes, Due 3/7/2036 (Swiss franc-denominated) 	2.10 % 	362 	—
2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated) 	2.94 % 	750 	773
1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated) 	1.73 % 	964 	993
2.80% 20-Year Senior Notes, Due 10/15/2041 	2.90 % 	1,200 	1,200
1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated) 	1.77 % 	1,339 	1,380
2.069% 20-Year Senior Notes, Due 10/20/2042 (Japanese yen-denominated) 	2.13 % 	91 	104
5.404% 20-Year Senior Notes, Due 8/10/2043 	5.50 % 	600 	600
2.02% 20-Year Senior Notes, Due 9/6/2043 (Japanese yen-denominated) 	2.06 % 	180 	206
5.30% 30-Year Senior Notes, Due 2/1/2044 	5.37 % 	400 	400
4.10% 30-Year Senior Notes, Due 8/15/2047 	4.23 % 	750 	750
1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated) 	1.98 % 	1,071 	1,104
2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated) 	2.06 % 	803 	828
2.382% 30-Year Senior Notes, Due 10/18/2052 (Japanese yen-denominated) 	2.43 % 	207 	236
Other 	74 	77
Total borrowings at par value 	35,481 	35,028
Unamortized discount 	(104) 	(113)
Unamortized debt issuance costs 	(179) 	(188)
Total borrowings at carrying value 	35,197 	34,727
Finance lease liabilities 	207 	190
Less: Short-term obligations and current maturities 	5,121 	3,609
Long-term obligations 	$ 	30,284 	$ 	31,308
The effective interest rates for the fixed-rate debt include the stated interest on the notes, the accretion of any discounts/premiums and the amortization of any debt
issuance costs.
See Note 10 for fair value information pertaining to the company’s long-term borrowings.
Credit Facilities
The company has a revolving credit facility (the Facility) with a bank group that provides for up to $5.00 billion of unsecured multi-currency revolving credit. The
Facility expires on January 7, 2027. The revolving credit agreement calls for interest at either a Term Secured Overnight Financing Rate (SOFR), a Euro Interbank
Offered Rate (EURIBOR)-based rate (for funds drawn in euro), or a rate based on the prime lending rate of the agent bank, at the company’s option. The agreement
contains affirmative, negative and financial covenants, and events of default customary for facilities of this type. The covenants in the Facility include a
Consolidated Net Interest Coverage Ratio (Consolidated EBITDA to Consolidated Net Interest Expense), as such terms are defined in the Facility. Specifically, the
company has agreed that, so long as any lender has any commitment under the Facility, any letter of credit is outstanding under the Facility, or any loan or other
obligation is outstanding under the Facility, it will maintain a minimum Consolidated Net Interest Coverage Ratio of 3.5:1.0 as of the last day of any fiscal quarter.
As of June 29, 2024, no borrowings were outstanding under the Facility, although available capacity was reduced by immaterial outstanding letters of credit.
16

-- 16 of 38 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Commercial Paper Programs
The company has commercial paper programs pursuant to which it may issue and sell unsecured, short-term promissory notes (CP Notes). Under the U.S. program,
a) maturities may not exceed 397 days from the date of issue and b) the CP Notes are issued on a private placement basis under customary terms in the commercial
paper market and are not redeemable prior to maturity nor subject to voluntary prepayment. Under the euro program, maturities may not exceed 183 days and may
be denominated in euro, U.S. dollars, Japanese yen, British pounds sterling, Swiss franc, Canadian dollars or other currencies. Under both programs, the CP Notes
are issued at a discount from par (or premium to par, in the case of negative interest rates), or, alternatively, are sold at par and bear varying interest rates on a fixed
or floating basis.
Senior Notes
Interest is payable annually on the euro and Swiss franc-denominated fixed rate senior notes and semi-annually on all other senior notes. Each of the U.S. dollar and
euro-denominated fixed rate senior notes and Japanese yen-denominated private placement notes may be redeemed at a redemption price of 100% of the principal
amount plus a specified make-whole premium and accrued interest, together with swap breakage costs payable to holders of Japanese yen-denominated private
placement notes who have entered into cross-currency swap agreements. The company is subject to certain affirmative and negative covenants under the indentures
and note purchase agreement governing the senior notes, the most restrictive of which limits the ability of the company to pledge certain property and assets as
security under borrowing arrangements. The company was in compliance with all covenants related to its senior notes at June 29, 2024.
Thermo Fisher Scientific (Finance I) B.V. (Thermo Fisher International), a wholly-owned finance subsidiary of the company, issued each of the following notes
outstanding as of June 29, 2024, included in the table above (collectively, the “Euronotes”) in registered public offerings: the 0.00% Senior Notes due 2025, the
0.80% Senior Notes due 2030, the 1.125% Senior Notes due 2033, the 1.625% Senior Notes due 2041, and the 2.00% Senior Notes due 2051. The company has
fully and unconditionally guaranteed all of Thermo Fisher International’s obligations under the Euronotes and all of Thermo Fisher International’s other debt
securities, and no other subsidiary of the company will guarantee these obligations. Thermo Fisher International is a “finance subsidiary” as defined in Rule 13-
01(a)(4)(vi) of the Exchange Act, with no assets or operations other than those related to the issuance, administration and repayment of the Euronotes and other debt
securities issued by Thermo Fisher International from time to time. The financial condition, results of operations and cash flows of Thermo Fisher International are
consolidated in the financial statements of the company.
Note 8. Commitments and Contingencies
Environmental Matters
The company is currently involved in various stages of investigation and remediation related to environmental matters. The company cannot predict all potential
costs related to environmental remediation matters and the possible impact on future operations given the uncertainties regarding the extent of the required cleanup,
the complexity and interpretation of applicable laws and regulations, the varying costs of alternative cleanup methods and the extent of the company’s
responsibility. Expenses for environmental remediation matters related to the costs of installing, operating and maintaining groundwater-treatment systems and
other remedial activities related to historical environmental contamination at the company’s domestic and international facilities were not material in any period
presented. At June 29, 2024, there have been no material changes to the accruals for pending environmental-related matters disclosed in the company’s 2023
financial statements and notes included in the company’s Annual Report on Form 10-K. While management believes the accruals for environmental remediation are
adequate based on current estimates of remediation costs, the company may be subject to additional remedial or compliance costs due to future events such as
changes in existing laws and regulations, changes in agency direction or enforcement policies, developments in remediation technologies or changes in the conduct
of the company’s operations, which could have a material adverse effect on the company’s financial position, results of operations and cash flows.
Litigation and Related Contingencies
The company is involved in various disputes, governmental and/or regulatory inspections, inquiries, investigations and proceedings, and litigation matters that arise
from time to time in the ordinary course of business. The disputes and litigation matters include product liability, intellectual property, employment and commercial
issues. Due to the inherent uncertainties associated with pending litigation or claims, the company cannot predict the outcome, nor, with respect to certain pending
litigation or claims where no liability has been accrued, make a meaningful estimate of the reasonably possible loss or range of loss that could result from an
unfavorable outcome. The company has no material accruals for pending litigation or claims for which accrual amounts are not disclosed in the company’s 2023
financial statements and notes included in the company’s Annual Report on Form 10-K, nor are material losses deemed probable for such matters. It is reasonably
possible, however, that
17

-- 17 of 38 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
an unfavorable outcome that exceeds the company’s current accrual estimate, if any, for one or more such matters could have a material adverse effect on the
company’s results of operations, financial position and cash flows.
Product Liability, Workers Compensation and Other Personal Injury Matters
The company is involved in various proceedings and litigation that arise from time to time in connection with product liability, workers compensation and other
personal injury matters. At June 29, 2024, there have been no material changes to the accruals for pending product liability, workers compensation, and other
personal injury matters disclosed in the company’s 2023 financial statements and notes included in the company’s Annual Report on Form 10-K. Although the
company believes that the amounts accrued and estimated insurance recoveries are probable and appropriate based on available information, including actuarial
studies of loss estimates, the process of estimating losses and insurance recoveries involves a considerable degree of judgment by management and the ultimate
amounts could vary, which could have a material adverse effect on the company’s results of operations, financial position, and cash flows. Insurance contracts do
not relieve the company of its primary obligation with respect to any losses incurred. The collectability of amounts due from its insurers is subject to the solvency
and willingness of the insurer to pay, as well as the legal sufficiency of the insurance claims. Management monitors the payment history as well as the financial
condition and ratings of its insurers on an ongoing basis.
Note 9. Comprehensive Income/(Loss) and Shareholders' Equity
Comprehensive Income/(Loss)
Changes in each component of accumulated other comprehensive income/(loss), net of tax, are as follows:
(In millions)
Currency
translation
adjustment
Unrealized
gains/(losses) on
available-for-sale
debt securities
Unrealized
gains/(losses) on
hedging
instruments
Pension and
other
postretirement
benefit
liability
adjustment 	Total
Three months ended June 29, 2024
Balance at March 30, 2024 	$ 	(2,482) $ 	(1) 	$ 	(27) 	$ 	(254) 	$ 	(2,764)
Other comprehensive income/(loss) before reclassifications 	346 	— 	— 	— 	347
Amounts reclassified from accumulated other
comprehensive income/(loss) 	3 	— 	1 	1 	5
Net other comprehensive income/(loss) 	349 	— 	1 	1 	351
Balance at June 29, 2024 	$ 	(2,133) $ 	(1) 	$ 	(26) 	$ 	(253) 	$ 	(2,413)
Six months ended June 29, 2024
Balance at December 31, 2023 	$ 	(2,941) $ 	— 	$ 	(28) 	$ 	(255) 	$ 	(3,224)
Other comprehensive income/(loss) before reclassifications 	802 	(1) 	— 	1 	802
Amounts reclassified from accumulated other
comprehensive income/(loss) 	6 	— 	1 	1 	9
Net other comprehensive income/(loss) 	808 	(1) 	1 	2 	811
Balance at June 29, 2024 	$ 	(2,133) $ 	(1) 	$ 	(26) 	$ 	(253) 	$ 	(2,413)
18

-- 18 of 38 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Note 10. Fair Value Measurements and Fair Value of Financial Instruments
Fair Value Measurements
The following tables present information about the company’s financial assets and liabilities measured at fair value on a recurring basis:
June 29,
Quoted
prices in
active
markets
Significant
other
observable
inputs
Significant
unobservable
inputs
(In millions) 	2024 	(Level 1) 	(Level 2) 	(Level 3)
Assets
Cash equivalents 	$ 	3,937 	$ 	3,937 	$ 	— 	$ 	—
Bank time deposits 	1,750 	1,750 	— 	—
Investments 	19 	19 	— 	—
Insurance contracts 	229 	— 	229 	—
Derivative contracts 	479 	— 	479 	—
Total assets 	$ 	6,414 	$ 	5,706 	$ 	708 	$ 	—
Liabilities
Derivative contracts 	$ 	23 	$ 	— 	$ 	23 	$ 	—
Contingent consideration 	12 	— 	— 	12
Total liabilities 	$ 	35 	$ 	— 	$ 	23 	$ 	12
December 31,
Quoted
prices in
active
markets
Significant
other
observable
inputs
Significant
unobservable
inputs
(In millions) 	2023 	(Level 1) 	(Level 2) 	(Level 3)
Assets
Cash equivalents 	$ 	5,021 	$ 	5,021 	$ 	— 	$ 	—
Bank time deposits 	3 	3 	— 	—
Investments 	20 	20 	— 	—
Insurance contracts 	210 	— 	210 	—
Derivative contracts 	8 	— 	8 	—
Total assets 	$ 	5,262 	$ 	5,044 	$ 	218 	$ 	—
Liabilities
Derivative contracts 	$ 	290 	$ 	— 	$ 	290 	$ 	—
Contingent consideration 	87 	— 	— 	87
Total liabilities 	$ 	377 	$ 	— 	$ 	290 	$ 	87
The company determines the fair value of its insurance contracts by obtaining the cash surrender value of the contracts from the issuer. The fair value of derivative
contracts is the estimated amount that the company would receive/pay upon liquidation of the contracts, taking into account the change in interest rates and
currency exchange rates. The company initially measures the fair value of acquisition-related contingent consideration based on amounts expected to be transferred
(probability-weighted) discounted to present value. Changes to the fair values of contingent consideration are recorded in selling, general and administrative
expense.
In the six-month periods ended June 29, 2024 and July 1, 2023 the company recorded $10 million and $(44) million, respectively, of net gains/(losses) on
investments, which are included in other income/(expense) in the accompanying statements of income.
The following table provides a rollforward of the fair value, as determined by level 3 inputs (such as likelihood of achieving production or revenue milestones, as
well as changes in the fair values of the investments underlying a recapitalization investment portfolio), of the contingent consideration.
19

-- 19 of 38 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Three months ended 	Six months ended
June 29, 	July 1, 	June 29, 	July 1,
(In millions) 	2024 	2023 	2024 	2023
Contingent consideration
Beginning balance 	$ 	83 	$ 	136 	$ 	87 	$ 	174
Acquisitions (including assumed balances) 	— 	1 	— 	1
Payments 	— 	(43) 	(2) 	(58)
Changes in fair value included in earnings 	(72) 	(4) 	(74) 	(27)
Ending balance 	$ 	12 	$ 	90 	$ 	12 	$ 	90
Derivative Contracts
The following table provides the aggregate notional value of outstanding derivative contracts.
(In millions) 	June 29, 2024 	December 31, 2023
Cross-currency interest rate swaps designated as net investment hedge - euro 	$ 	1,000 	$ 	1,000
Cross-currency interest rate swaps designated as net investment hedge - Japanese yen 	4,650 	4,650
Cross-currency interest rate swaps designated as net investment hedge - Swiss franc 	2,500 	2,500
Currency exchange contracts 	1,216 	1,567
While certain derivatives are subject to netting arrangements with counterparties, the company does not offset derivative assets and liabilities within the balance
sheet. The following tables present the fair value of derivative instruments in the accompanying balance sheets and statements of income.
Fair value – assets 	Fair value – liabilities
June 29, 	December 31, 	June 29, 	December 31,
(In millions) 	2024 	2023 	2024 	2023
Derivatives designated as hedging instruments
Cross-currency interest rate swaps (a) 	$ 	478 	$ 	5 	$ 	22 	$ 	287
Derivatives not designated as hedging instruments
Currency exchange contracts (b) 	1 	3 	1 	3
Total derivatives 	$ 	479 	$ 	8 	$ 	23 	$ 	290
(a) The fair value of the cross-currency interest rate swaps is included in the accompanying balance sheet under the caption other assets or other long-term liabilities.
(b) The fair value of the currency exchange contracts is included in the accompanying balance sheet under the captions other current assets or other accrued expenses.
Gain (loss) recognized
Three months ended 	Six months ended
June 29, 	July 1, 	June 29, 	July 1,
(In millions) 	2024 	2023 	2024 	2023
Derivatives designated as cash flow hedges
Interest rate swaps
Amount reclassified from accumulated other comprehensive items to
interest expense 	$ 	(1) 	$ 	— 	$ 	(2) 	$ 	—
Amount reclassified from accumulated other comprehensive items to other
income/(expense) 	— 	(1) 	— 	(5)
Financial instruments designated as net investment hedges
Foreign currency-denominated debt and other payables
Included in currency translation adjustment within other comprehensive
items 	85 	(62) 	361 	(206)
Cross-currency interest rate swaps
Included in currency translation adjustment within other comprehensive
items 	293 	59 	736 	50
Included in interest expense 	68 	16 	134 	33
20

-- 20 of 38 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Gain (loss) recognized
Three months ended 	Six months ended
June 29, 	July 1, 	June 29, 	July 1,
(In millions) 	2024 	2023 	2024 	2023
Derivatives not designated as hedging instruments
Currency exchange contracts
Included in cost of product revenues 	4 	— 	7 	(3)
Included in other income/(expense) 	(4) 	(25) 	(10) 	(2)
Gains and losses recognized on currency exchange contracts are included in the accompanying statements of income together with the corresponding, offsetting
losses and gains on the underlying hedged transactions.
The company uses foreign currency-denominated debt, certain foreign currency-denominated payables, and cross-currency interest rate swaps to partially hedge its
net investments in foreign operations against adverse movements in exchange rates. A portion of the company’s euro-denominated senior notes, certain foreign
currency-denominated payables, and its cross-currency interest rate swaps have been designated as, and are effective as, economic hedges of part of the net
investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments
and certain foreign currency-denominated payables, and contract fair value changes on the cross-currency interest rate swaps, excluding interest accruals, are
included in currency translation adjustment within other comprehensive items and shareholders’ equity.
See Note 1 to the consolidated financial statements for 2023 included in the company’s Annual Report on Form 10-K for additional information on the company’s
risk management objectives and strategies.
Fair Value of Other Financial Instruments
The carrying value and fair value of the company’s debt instruments are as follows:
June 29, 2024 	December 31, 2023
Carrying 	Fair 	Carrying 	Fair
(In millions) 	value 	value 	value 	value
Senior notes 	$ 	35,123 	$ 	31,983 	$ 	34,650 	$ 	32,191
Other 	74 	74 	77 	77
$ 	35,197 	$ 	32,057 	$ 	34,727 	$ 	32,268
The fair value of debt instruments, excluding private placement notes, was determined based on quoted market prices and on borrowing rates available to the
company at the respective period ends, which represent level 2 measurements. The fair value of private placement notes was determined based on internally
developed pricing models and unobservable inputs, which represent level 3 measurements.
Note 11. Supplemental Cash Flow Information
Six months ended
(In millions) 	June 29, 2024 	July 1, 2023
Non-cash investing and financing activities
Acquired but unpaid property, plant and equipment 	$ 	166 	$ 	231
Declared but unpaid dividends 	151 	137
Issuance of stock upon vesting of restricted stock units 	71 	97
Excise tax from stock repurchases 	28 	29
Cash, cash equivalents and restricted cash is included in the accompanying balance sheet as follows:
(In millions) 	June 29, 2024 	December 31, 2023
Cash and cash equivalents 	$ 	7,073 	$ 	8,077
Restricted cash included in other current assets 	11 	6
Restricted cash included in other assets 	14 	14
Cash, cash equivalents and restricted cash 	$ 	7,097 	$ 	8,097
Amounts included in restricted cash primarily represent funds held as collateral for bank guarantees and incoming cash in China awaiting government
administrative clearance.
21

-- 21 of 38 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Note 12. Restructuring and Other Costs
In the first six months of 2024, restructuring and other costs primarily included continuing charges for headcount reductions and facility consolidations in an effort
to streamline operations, impairment of long-lived assets, and, to a lesser extent, net charges for pre-acquisition litigation and other matters. In 2024, severance
actions associated with facility consolidations and cost reduction measures affected approximately 1% of the company’s workforce.
As of August 2, 2024, the company has identified restructuring actions that will result in additional charges of approximately $80 million, primarily in 2024, and
expects to identify additional actions in future periods which will be recorded when specified criteria are met, such as communication of benefit arrangements or
when the costs have been incurred.
Restructuring and other costs by segment are as follows:
Three months ended 	Six months ended
(In millions) 	June 29, 2024 	June 29, 2024
Life Sciences Solutions 	$ 	14 	$ 	16
Analytical Instruments 	3 	10
Specialty Diagnostics 	— 	5
Laboratory Products and Biopharma Services 	57 	71
Corporate 	3 	4
$ 	77 	$ 	106
The following table summarizes the changes in the company’s accrued restructuring balance, which is included in other accrued expenses in the accompanying
balance sheet. Other amounts reported as restructuring and other costs in the accompanying statements of income have been summarized in the notes to the table.
(In millions) 	Total (a)
Balance at December 31, 2023 	$ 	60
Net restructuring charges incurred in 2024 (b) 	51
Payments 	(60)
Currency translation 	(2)
Balance at June 29, 2024 	$ 	49
(a) The movements in the restructuring liability principally consist of severance and other costs associated with facility consolidations.
(b) Excludes $55 million of net charges, principally $47 million of charges for impairment of long-lived assets in the Laboratory Products and Biopharma Services and Life
Sciences Solutions segments.
The company expects to pay accrued restructuring costs primarily through 2024.
22

-- 22 of 38 --

THERMO FISHER SCIENTIFIC INC.
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934 (the Exchange Act), are made throughout this
Management’s Discussion and Analysis of Financial Condition and Results of Operations. Any statements contained herein that are not statements of historical fact
may be deemed to be forward-looking statements, including without limitation statements regarding: projections of revenues, expenses, earnings, margins, tax rates,
tax provisions, cash flows, pension and benefit obligations and funding requirements, and our liquidity position; cost reductions, restructuring activities, new
product and service developments, competitive strengths or market position, acquisitions or divestitures; growth, declines and other trends in markets we sell into;
new or modified laws, regulations and accounting pronouncements; outstanding claims, legal proceedings, tax audits and assessments and other contingent
liabilities; foreign currency exchange rates and fluctuations in those rates; general economic and capital markets conditions; the timing of any of the foregoing;
assumptions underlying any of the foregoing; the COVID-19 pandemic; and any other statements that address events or developments that Thermo Fisher intends
or believes will or may occur in the future. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “seeks,” “estimates,” and similar
expressions are intended to identify forward-looking statements, although not all forward-looking statements are accompanied by such words. While the company
may elect to update forward-looking statements in the future, it specifically disclaims any obligation to do so, even if the company’s estimates change, and readers
should not rely on those forward-looking statements as representing the company’s views as of any date subsequent to the date of the filing of this report.
A number of important factors could cause the results of the company to differ materially from those indicated by such forward-looking statements, including those
detailed under the caption “Risk Factors” in the company’s Annual Report on Form 10-K for the year ended December 31, 2023 (which is on file with the SEC).
Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to:
the COVID-19 pandemic; the need to develop new products and adapt to significant technological change; implementation of strategies for improving growth;
general economic conditions and related uncertainties; dependence on customers’ capital spending policies and government funding policies; the effect of economic
and political conditions and exchange rate fluctuations on international operations; use and protection of intellectual property; the effect of changes in governmental
regulations; any natural disaster, public health crisis or other catastrophic event; and the effect of laws and regulations governing government contracts, as well as
the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected.
The company refers to various amounts or measures not prepared in accordance with generally accepted accounting principles (non-GAAP measures). These non-
GAAP measures are further described and reconciled to their most directly comparable amount or measure under the section “Non-GAAP Measures” later in this
“Management’s Discussion and Analysis of Financial Condition and Results of Operations.”
Certain amounts and percentages reported within this Quarterly Report on Form 10-Q are presented and calculated based on underlying unrounded amounts. As a
result, the sum of components may not equal corresponding totals due to rounding.
Overview
Thermo Fisher Scientific Inc. enables customers to make the world healthier, cleaner and safer by helping them accelerate life sciences research, solve complex
analytical challenges, increase laboratory productivity, and improve patient health through diagnostics and the development and manufacture of life-changing
therapies. Markets served include pharmaceutical and biotech, academic and government, industrial and applied, as well as healthcare and diagnostics. The
company’s operations fall into four segments (Note 4): Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics and Laboratory Products and
Biopharma Services.
Consolidated Results
Three months ended 	Six months ended
June 29, 	July 1, 	June 29, 	July 1,
(Dollars in millions except per share amounts) 	2024 	2023 	Change 	2024 	2023 	Change
Revenues 	$ 	10,541 	$ 	10,687 	(1) % $ 	20,886 	$ 	21,397 	(2) %
GAAP operating income 	1,820 	1,578 	15 % 	3,483 	3,141 	11 %
GAAP operating income margin 	17.3 % 	14.8 % 	2.5 pt 	16.7 % 	14.7 % 	2.0 pt
Adjusted operating income (non-GAAP measure) 	2,347 	2,370 	(1) % 	4,625 	4,700 	(2) %
Adjusted operating income margin (non-GAAP measure) 	22.3 % 	22.2 % 	0.1 pt 	22.1 % 	22.0 % 	0.1 pt
GAAP diluted earnings per share attributable to Thermo Fisher
Scientific Inc. 	4.04 	3.51 	15 % 	7.50 	6.83 	10 %
Adjusted earnings per share (non-GAAP measure) 	5.37 	5.15 	4 % 	10.47 	10.18 	3 %
23

-- 23 of 38 --

THERMO FISHER SCIENTIFIC INC.
Organic Revenue Growth
Three months ended 	Six months ended
June 29, 2024 	June 29, 2024
Revenue growth 	(1)% 	(2)%
Impact of acquisitions 	0 % 	0 %
Impact of currency translation 	(1)% 	0 %
Organic revenue growth (non-GAAP measure) 	(1)% 	(2)%
Since 2020, the Life Sciences Solutions and Specialty Diagnostics segments as well as the laboratory products business have supported COVID-19 diagnostic
testing. Additionally, our pharma services business has provided our pharma and biotech customers with the services they needed to develop and produce vaccines
and therapies globally. Since the company’s acquisition of PPD in December 2021, the clinical research business has continued to play a leading role in supporting
the clinical trials for COVID-19 vaccines and therapies. These positive impacts are expected to continue at much lower levels in 2024 as customer testing as well as
therapy and vaccine demand declines. Sales of products related to COVID-19 testing were $0.02 billion and $0.08 billion in the second quarter of 2024 and 2023,
respectively, and $0.05 billion and $0.22 billion in the first six months of 2024 and 2023, respectively.
During the second quarter of 2024, revenues from pharma and biotech customers declined due to reduced demand for our products and services that support
COVID-19 vaccines and therapies as well as a more muted macroeconomic environment, partially offset through strong commercial execution. Revenues in the
academic and government as well as the industrial and applied markets grew due to demand for analytical instruments. The diagnostics and healthcare market
declined due to decreased demand for COVID-19 testing products. During the second quarter of 2024, sales growth was strong in Asia-Pacific, including China.
Sales in Europe grew slightly and in North America declined due to decreased demand for COVID-19 related products, as well as a challenging macroeconomic
environment. Contributions to organic revenue during the second quarter of 2024 from the Analytical Instruments and Specialty Diagnostics segments were more
than offset by declines in the Laboratory Products and Biopharma Services and Life Sciences Solutions segments.
During the first six months of 2024, all of our end markets were negatively impacted by a more muted macroeconomic environment and moderate economic
activity in China. Revenues from pharma and biotech and diagnostics and healthcare customers declined due to demand for COVID-19 related products and
services. Revenues in the academic and government as well as the industrial and applied markets were flat. During the first six months of 2024, sales grew slightly
in Asia-Pacific, including China. Sales growth in Europe was flat and sales in North America declined due to decreased demand for COVID-19 related products.
Contributions to organic revenue during the first six months of 2024 from the Specialty Diagnostics and Analytical Instruments segments were more than offset by
declines in the Life Sciences Solutions and Laboratory Products and Biopharma Services segments.
The company continues to execute its proven growth strategy which consists of three pillars:
• High-impact innovation,
• Our trusted partner status with customers, and
• Our unparalleled commercial engine.
GAAP operating income margin and adjusted operating income margin increased in the second quarter of 2024 due primarily to strong productivity improvements,
partially offset by unfavorable business mix. GAAP operating income margin in the second quarter of 2024 was also impacted by net credits for changes in
estimates of contingent acquisition consideration, lower levels of restructuring and other charges incurred for headcount reductions and facility consolidations in an
effort to streamline operations (Note 12), and, to a lesser extent, lower amortization expense.
GAAP operating income margin and adjusted operating income margin increased in the first six months of 2024 due primarily to strong productivity improvements,
partially offset by unfavorable business mix. GAAP operating income margin during the first six months of 2024 was also impacted by lower levels of restructuring
and other charges incurred for headcount reductions and facility consolidations in an effort to streamline operations (Note 12).
The company’s references to strategic investments generally refer to targeted spending for enhancing commercial capabilities, including expansion of geographic
sales reach and e-commerce platforms, marketing initiatives, expanded service and operational infrastructure, research and development projects and other
expenditures to enhance the customer experience, as well as incentive compensation and recognition for employees. The company’s references throughout this
discussion to productivity improvements generally refer to improved cost efficiencies from its Practical Process Improvement (PPI) business system to address
inflation, including reduced costs resulting from implementing continuous improvement methodologies,
24

-- 24 of 38 --

THERMO FISHER SCIENTIFIC INC.
global sourcing initiatives, a lower cost structure following restructuring actions including headcount reductions and consolidation of facilities, and low cost region
manufacturing.
Notable Recent Acquisitions
On January 3, 2023, the company acquired, within the Specialty Diagnostics segment, The Binding Site Group, a U.K.-based provider of specialty diagnostic assays
and instruments to improve the diagnosis and management of blood cancers and immune system disorders. The acquisition expands the segment’s portfolio with the
addition of pioneering innovation in diagnostics and monitoring for multiple myeloma.
On August 14, 2023, the company acquired, within the Laboratory Products and Biopharma Services segment, CorEvitas, LLC, a U.S.-based provider of
regulatory-grade, real-world evidence for approved medical treatments and therapies. The acquisition expands the segment’s portfolio with the addition of highly
complementary real-world evidence solutions to enhance decision-making as well as the time and cost of drug development.
On July 10, 2024, the company acquired, within the Life Sciences Solutions segment, Olink Holding AB (publ), a Swedish-based provider of next-generation
proteomics solutions. The acquisition enhances the segment’s capabilities in the high-growth proteomics market with the addition of highly differentiated solutions.
It also complements the existing life sciences and mass spectrometry offerings, accelerating protein biomarker discovery and providing strong synergy
opportunities.
Segment Results
The company’s management evaluates segment operating performance using operating income before certain charges/credits as defined in Note 4 to the
Consolidated Financial Statements of the company’s Annual Report on Form 10-K for 2023. Accordingly, the following segment data are reported on this basis.
Three months ended 	Six months ended
June 29, 	July 1, 	June 29, 	July 1,
(Dollars in millions) 	2024 	2023 	2024 	2023
Revenues
Life Sciences Solutions 	$ 	2,355 	$ 	2,463 	$ 	4,640 	$ 	5,075
Analytical Instruments 	1,782 	1,749 	3,469 	3,472
Specialty Diagnostics 	1,117 	1,109 	2,227 	2,217
Laboratory Products and Biopharma Services 	5,758 	5,831 	11,480 	11,594
Eliminations 	(470) 	(465) 	(930) 	(961)
Consolidated revenues 	$ 	10,541 	$ 	10,687 	$ 	20,886 	$ 	21,397
Life Sciences Solutions
Three months ended
Organic (non-
GAAP measure)	(Dollars in millions) June 29,
2024 July 1,
2023 Total
Change Currency
Translation Acquisitions/
Divestitures
Revenues 	$ 	2,355 	$ 	2,463 	(4) % 	(1)% 	0 % 	(3)%
Segment income 	865 	817 	6 %
Segment income margin 	36.7 % 	33.2 % 	3.5 pt
The decrease in organic revenues in the second quarter of 2024 was primarily due to moderation in COVID-19 related revenue, partially offset by growth in the
biosciences business. The increase in segment income margin resulted primarily from exceptionally strong productivity improvements, partially offset by
unfavorable volume pull-through.
Six months ended
Organic (non-
GAAP measure)	(Dollars in millions)
June 29,
2024
July 1,
2023
Total
Change
Currency
Translation
Acquisitions/
Divestitures
Revenues 	$ 	4,640 	$ 	5,075 	(9) % 	(1)% 	0 % 	(8)%
Segment income 	1,705 	1,653 	3 %
Segment income margin 	36.7 % 	32.6 % 	4.1 pt
The decrease in organic revenues in the first six months of 2024 was primarily due to moderation in COVID-19 related revenue. The increase in segment income
margin resulted primarily from exceptionally strong productivity improvements, partially offset by unfavorable volume pull-through.
25

-- 25 of 38 --

THERMO FISHER SCIENTIFIC INC.
Analytical Instruments
Three months ended
Organic (non-
GAAP measure)	(Dollars in millions)
June 29,
2024
July 1,
2023
Total
Change
Currency
Translation
Acquisitions/
Divestitures
Revenues 	$ 	1,782 	$ 	1,749 	2 % 	(1)% 	0 % 	3 %
Segment income 	439 	432 	1 %
Segment income margin 	24.6 % 	24.7 % 	(0.1) pt
The increase in organic revenues in the second quarter of 2024 was primarily due to very strong growth in the electron microscopy business, partially offset by
declines in the other instrumentation businesses. The decrease in segment income margin resulted primarily from unfavorable business mix and strategic
investments, partially offset by strong productivity improvements.
Six months ended
Organic (non-
GAAP measure)	(Dollars in millions) June 29,
2024 July 1,
2023 Total
Change Currency
Translation Acquisitions/
Divestitures
Revenues 	$ 	3,469 	$ 	3,472 	0 % 	(1)% 	0 % 	1 %
Segment income 	838 	853 	(2) %
Segment income margin 	24.2 % 	24.6 % 	(0.4) pt
The increase in organic revenues in the first six months of 2024 was primarily due to very strong growth in the electron microscopy business, partially offset by
declines in the other instrumentation businesses. The decrease in segment income margin resulted primarily from unfavorable business mix and strategic
investments, partially offset by strong productivity improvements.
Specialty Diagnostics
Three months ended
Organic (non-
GAAP measure)	(Dollars in millions)
June 29,
2024
July 1,
2023
Total
Change
Currency
Translation
Acquisitions/
Divestitures
Revenues 	$ 	1,117 	$ 	1,109 	1 % 	(1)% 	0 % 	1 %
Segment income 	299 	297 	1 %
Segment income margin 	26.7 % 	26.7 % 	0.0 pt
The increase in organic revenues in the second quarter of 2024 was primarily driven by underlying growth in the transplant diagnostics and immunodiagnostics
businesses, as well as in the healthcare market channel, largely offset by decreased demand for products addressing diagnosis of COVID-19. Segment income
margin was flat in the second quarter of 2024 when compared to 2023 due to good productively improvements, offset by strategic investments.
Six months ended
Organic (non-
GAAP measure)	(Dollars in millions)
June 29,
2024
July 1,
2023
Total
Change
Currency
Translation
Acquisitions/
Divestitures
Revenues 	$ 	2,227 	$ 	2,217 	0 % 	0 % 	0 % 	1 %
Segment income 	593 	577 	3 %
Segment income margin 	26.6 % 	26.0 % 	0.6 pt
The increase in organic revenues in the first six months of 2024 was driven by underlying growth in the transplant diagnostics and immunodiagnostics businesses,
as well as in the healthcare market channel, largely offset by decreased demand for products addressing diagnosis of COVID-19. The increase in segment income
margin was due to favorable business mix and productivity improvements, partially offset by strategic investments.
26

-- 26 of 38 --

THERMO FISHER SCIENTIFIC INC.
Laboratory Products and Biopharma Services
Three months ended
Organic (non-
GAAP measure)	(Dollars in millions) June 29,
2024 July 1,
2023 Total
Change Currency
Translation Acquisitions/
Divestitures
Revenues 	$ 	5,758 	$ 	5,831 	(1) % 	0 % 	0 % 	(1)%
Segment income 	745 	824 	(10) %
Segment income margin 	12.9 % 	14.1 % 	(1.2) pt
The decrease in organic revenues in the second quarter of 2024 was primarily due to decreased demand in COVID-19 vaccines and therapies, partially offset by
growth in the clinical research business. The decrease in segment income margin was primarily due to unfavorable business mix and strategic investments, partially
offset by strong productivity improvements.
Six months ended
Organic (non-
GAAP measure)	(Dollars in millions)
June 29,
2024
July 1,
2023
Total
Change
Currency
Translation
Acquisitions/
Divestitures
Revenues 	$ 	11,480 	$ 	11,594 	(1) % 	0 % 	0 % 	(1)%
Segment income 	1,489 	1,617 	(8) %
Segment income margin 	13.0 % 	14.0 % 	(1.0) pt
The decrease in organic revenues in the first six months of 2024 was primarily due to decreased demand in COVID-19 vaccines and therapies, partially offset by
growth in the clinical research business. The decrease in segment income margin was primarily due to unfavorable business mix, partially offset by productivity
improvements.
Non-operating Items
Three months ended 	Six months ended
June 29, 	July 1, 	June 29, 	July 1,
(Dollars and shares in millions) 	2024 	2023 	2024 	2023
Net interest expense 	$ 	59 	$ 	148 	$ 	143 	$ 	302
GAAP other income/(expense) 	5 	— 	14 	(46)
Adjusted other income/(expense) (non-GAAP measure) 	4 	(1) 	3 	(1)
GAAP tax rate 	7.2 % 	3.6 % 	12.2 % 	3.5 %
Adjusted tax rate (non-GAAP measure) 	10.0 % 	10.0 % 	10.2 % 	10.0 %
Weighted average diluted shares 	383 	388 	383 	388
Net interest expense (interest expense less interest income) in the second quarter and first six months of 2024 decreased due primarily to higher cash, and cash
equivalents and short-term investments balances, as well as higher interest rates on these balances when compared to the second quarter and first six months of
2023. The company’s net interest expense was reduced by approximately $67 million and $132 million in the second quarter and first six months of 2024,
respectively, as a result of its interest rate swap and cross-currency interest rate swap arrangements. In the second quarter and first six months of 2023, the
company’s net interest expense was reduced by approximately $16 million and $33 million, respectively, as a result of these arrangements (Note 10).
GAAP other income/(expense) and adjusted other income/(expense) includes currency transaction gains/losses on non-operating monetary assets and liabilities, and
net periodic pension benefit cost/income, excluding the service cost component. GAAP other income/(expense) in the first six months of 2024 and 2023 also
includes $10 million and $(43) million, respectively, of net gains/(losses) on investments.
The company’s GAAP tax rate increased in the first six months of 2024 compared to 2023 primarily due to $176 million of expense, net, for a provision associated
with a tax audit recorded in the first quarter of 2024. The company’s GAAP and adjusted tax rates in the first six months of 2024 were also impacted by a benefit of
$183 million, primarily in jurisdictions where the deferred tax assets are now expected to be realized due to forecasted income. The company’s GAAP and adjusted
tax rates in the first six months of 2023 were impacted by a tax benefit of $91 million, net of related tax expenses, from a foreign exchange loss on an intercompany
debt refinancing transaction in the second quarter of 2023. The company’s GAAP and adjusted tax rates in the six-month periods ended June 29, 2024 and July 1,
2023 were also impacted by $102 million and $144 million, respectively, of tax benefits resulting from capital losses generated as part of intra-entity transactions
(Note 5).
27

-- 27 of 38 --

THERMO FISHER SCIENTIFIC INC.
The effective tax rates in both 2024 and 2023 were also affected by relatively significant earnings in lower tax jurisdictions. Due primarily to the non-deductibility
of intangible asset amortization for tax purposes, the company’s cash payments for income taxes are higher than its income tax expense for financial reporting
purposes and are expected to total approximately $1.65 billion in 2024.
The company expects its GAAP effective tax rate in 2024 will be between 9% and 11%. The effective tax rate can vary significantly from period to period as a
result of discrete income tax factors and events. The company expects its adjusted tax rate will be approximately 10.5% in 2024.
The company has operations and a taxable presence in approximately 70 countries outside the U.S. Some of these countries have lower tax rates than the U.S. The
company’s ability to obtain a benefit from lower tax rates outside the U.S. is dependent on its relative levels of income in countries outside the U.S. and on the
statutory tax rates in those countries. Based on the dispersion of the company’s non-U.S. income tax provision among many countries, the company believes that a
change in the statutory tax rate in any individual country is not likely to materially affect the company’s income tax provision or net income, aside from any
resulting one-time adjustment to the company’s deferred tax balances to reflect a new rate.
Equity in earnings/losses of unconsolidated entities was impacted by an $88 million impairment of an equity method investment in the second quarter of 2024.
Weighted average diluted shares decreased in 2024 compared to 2023 due to share repurchases, net of option dilution.
Liquidity and Capital Resources
The company’s proven growth strategy has enabled it to generate free cash flow as well as access the capital markets. The company deploys its capital primarily via
mergers and acquisitions and secondarily via share buybacks and dividends.
(In millions) 	June 29, 2024 	December 31, 2023
Cash and cash equivalents 	$ 	7,073 	$ 	8,077
Short-term investments 	1,750 	3
Total debt 	35,404 	34,917
Approximately half of the company’s cash balances and cash flows from operations are from outside the U.S. The company uses its non-U.S. cash for needs outside
of the U.S. including acquisitions, capacity expansion, and repayment of third-party foreign debt by foreign subsidiaries. In addition, the company also transfers
cash to the U.S. using non-taxable intercompany transactions, including loans and returns of capital, as well as dividends where the related U.S. dividend received
deduction or foreign tax credit equals any tax cost arising from the dividends. As a result of using such means of transferring cash to the U.S., the company does not
expect any material adverse liquidity effects from its significant non-U.S. cash balances for the foreseeable future.
The company believes that its existing cash and cash equivalents and its future cash flow from operations together with available borrowing capacity under its
revolving credit agreement will be sufficient to meet the cash requirements of its existing businesses for the foreseeable future, including at least the next 24
months.
As of June 29, 2024, the company’s short-term obligations and current maturities of long-term obligations totaled $5.12 billion. The company has a revolving credit
facility with a bank group that provides up to $5.00 billion of unsecured multi-currency revolving credit (Note 7). If the company borrows under this facility, it
intends to leave undrawn an amount equivalent to outstanding commercial paper to provide a source of funds in the event that commercial paper markets are not
available. As of June 29, 2024, no borrowings were outstanding under the company’s revolving credit facility, although available capacity was reduced by
immaterial outstanding letters of credit.
Six months ended
(In millions) 	June 29, 2024 	July 1, 2023
Net cash provided by operating activities 	$ 	3,211 	$ 	2,269
Net cash used in investing activities 	(2,283) 	(3,585)
Net cash used in financing activities 	(1,936) 	(4,049)
Free cash flow (non-GAAP measure) 	2,583 	1,537
Operating Activities
During the first six months of 2024, cash provided by income was offset in part by investments in working capital. Changes in other assets and other liabilities used
cash of $0.57 billion primarily due to the timing of payments for compensation and income taxes. Cash payments for income taxes were $1.13 billion during the
first six months of 2024.
28

-- 28 of 38 --

THERMO FISHER SCIENTIFIC INC.
During the first six months of 2023, cash provided by income was offset in part by investments in working capital. Changes in other assets and other liabilities used
cash of $1.50 billion primarily due to the timing of payments for compensation and income taxes. A decrease in accounts payable used cash of $0.87 billion. Cash
payments for income taxes were $0.78 billion during the first six months of 2023.
Investing Activities
During the first six months of 2024, purchases of short-term investments used cash of $1.78 billion. The company’s investing activities also included purchases of
$0.65 billion of property, plant and equipment for capacity and capability investments.
During the first six months of 2023, acquisitions used cash of $2.75 billion. The company’s investing activities also included purchases of $0.74 billion of property,
plant and equipment for capacity and capability investments.
The company expects that for all of 2024, expenditures for property, plant and equipment, net of disposals, will be between $1.3 billion and $1.5 billion.
Financing Activities
During the first six months of 2024, issuance of debt provided $1.20 billion of cash. The company’s financing activities also included the repurchase of $3.00
billion of the company’s common stock (5.5 million shares) and the payment of $0.28 billion in cash dividends. On November 14, 2023, the Board of Directors
announced that it replaced the existing authorization to repurchase the company’s common stock, of which $1.00 billion was remaining, with a new authorization to
repurchase up to $4.00 billion of the company’s common stock. All of the shares of common stock repurchased by the company during the first quarter of 2024
were under this program. At August 2, 2024, authorization remained for $1.00 billion of future repurchases of the company’s common stock.
During the first six months of 2023, repayment of senior notes used cash of $1.00 billion. The company’s financing activities also included the repurchase of $3.00
billion of the company’s common stock (5.2 million shares) and the payment of $0.25 billion in cash dividends.
The company’s commitments for purchases of property, plant and equipment, contractual obligations and other commercial commitments, did not change materially
subsequent to December 31, 2023, except in connection with the completion of the Olink acquisition, which occurred on July 10, 2024 (Note 2).
Non-GAAP Measures
In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures
such as organic revenue growth, which is reported revenue growth, excluding the impacts of revenues from acquired/divested businesses and the effects of currency
translation. We report organic revenue growth because Thermo Fisher management believes that in order to understand the company’s short-term and long-term
financial trends, investors may wish to consider the impact of acquisitions/divestitures and foreign currency translation on revenues. Thermo Fisher management
uses organic revenue growth to forecast and evaluate the operational performance of the company as well as to compare revenues of current periods to prior
periods.
We report adjusted operating income, adjusted operating margin, adjusted other income/(expense), adjusted tax rate, and adjusted EPS. We believe that the use of
these non-GAAP financial measures, in addition to GAAP financial measures, helps investors to gain a better understanding of our core operating results and future
prospects, consistent with how management measures and forecasts the company’s core operating performance, especially when comparing such results to previous
periods, forecasts, and to the performance of our competitors. Such measures are also used by management in their financial and operating decision-making and for
compensation purposes. To calculate these measures we exclude, as applicable:
• Certain acquisition-related costs, including charges for the sale of inventories revalued at the date of acquisition, significant transaction/acquisition-related
costs, including changes in estimates of contingent acquisition-related consideration, and other costs associated with obtaining short-term financing
commitments for pending/recent acquisitions. We exclude these costs because we do not believe they are indicative of our normal operating costs.
• Costs/income associated with restructuring activities and large-scale abandonments of product lines, such as reducing overhead and consolidating
facilities. We exclude these costs because we believe that the costs related to restructuring activities and large-scale abandonment of product lines are not
indicative of our normal operating costs.
• Equity in earnings/losses of unconsolidated entities; impairments of long-lived assets; and certain other gains and losses that are either isolated or cannot
be expected to occur again with any predictability, including gains/losses on investments, the sale of businesses, product lines, and real estate, significant
litigation-related matters, curtailments/settlements of pension plans, and the early retirement of debt. We exclude these items because they are outside of
our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods.
29

-- 29 of 38 --

THERMO FISHER SCIENTIFIC INC.
• The expense associated with the amortization of acquisition-related intangible assets because a significant portion of the purchase price for acquisitions
may be allocated to intangible assets that have lives of up to 20 years. Exclusion of the amortization expense allows comparisons of operating results that
are consistent over time for both our newly acquired and long-held businesses and with both acquisitive and non-acquisitive peer companies.
• The noncontrolling interest and tax impacts of the above items and the impact of significant tax audits or events (such as changes in deferred taxes from
enacted tax rate/law changes), the latter of which we exclude because they are outside of our normal operations and difficult to forecast accurately for
future periods.
We report free cash flow, which is operating cash flow excluding net capital expenditures, to provide a view of the continuing operations’ ability to generate cash
for use in acquisitions and other investing and financing activities. The company also uses this measure as an indication of the strength of the company. Free cash
flow is not a measure of cash available for discretionary expenditures since we have certain non-discretionary obligations such as debt service that are not deducted
from the measure.
The non-GAAP financial measures of the company’s results of operations and cash flows included in this Form 10-Q are not meant to be considered superior to or a
substitute for the company’s results of operations prepared in accordance with GAAP. Reconciliations of such non-GAAP financial measures to the most directly
comparable GAAP financial measures are set forth within the “Consolidated Results” and “Segment Results” sections and below.
Three months ended 	Six months ended
June 29, 	July 1, 	June 29, 	July 1,
(Dollars in millions except per share amounts) 	2024 	2023 	2024 	2023
Reconciliation of adjusted operating income
GAAP operating income 	$ 	1,820 	$ 	1,578 	$ 	3,483 	$ 	3,141
Cost of revenues adjustments (a) 	1 	18 	17 	59
Selling, general and administrative expenses adjustments (b) 	(64) 	6 	(45) 	14
Restructuring and other costs (c) 	77 	183 	106 	295
Amortization of acquisition-related intangible assets 	513 	585 	1,065 	1,191
Adjusted operating income (non-GAAP measure) 	$ 	2,347 	$ 	2,370 	$ 	4,625 	$ 	4,700
Reconciliation of adjusted operating income margin
GAAP operating income margin 	17.3 % 	14.8 % 	16.7 % 	14.7 %
Cost of revenues adjustments (a) 	0.0 % 	0.2 % 	0.1 % 	0.3 %
Selling, general and administrative expenses adjustments (b) 	(0.6)% 	0.1 % 	(0.2)% 	0.1 %
Restructuring and other costs (c) 	0.7 % 	1.7 % 	0.5 % 	1.4 %
Amortization of acquisition-related intangible assets 	4.9 % 	5.4 % 	5.1 % 	5.5 %
Adjusted operating income margin (non-GAAP measure) 	22.3 % 	22.2 % 	22.1 % 	22.0 %
Reconciliation of adjusted other income/(expense)
GAAP other income/(expense) 	$ 	5 	$ 	— 	$ 	14 	$ 	(46)
Adjustments (d) 	— 	(1) 	(11) 	45
Adjusted other income/(expense) (non-GAAP measure) 	$ 	4 	$ 	(1) 	$ 	3 	$ 	(1)
Reconciliation of adjusted tax rate
GAAP tax rate 	7.2 % 	3.6 % 	12.2 % 	3.5 %
Adjustments (e) 	2.8 % 	6.4 % 	(2.0)% 	6.5 %
Adjusted tax rate (non-GAAP measure) 	10.0 % 	10.0 % 	10.2 % 	10.0 %
30

-- 30 of 38 --

THERMO FISHER SCIENTIFIC INC.
Three months ended 	Six months ended
June 29, 	July 1, 	June 29, 	July 1,
(Dollars in millions except per share amounts) 	2024 	2023 	2024 	2023
Reconciliation of adjusted earnings per share
GAAP diluted earnings per share (EPS) attributable to Thermo Fisher Scientific Inc. 	$ 	4.04 $ 	3.51 $ 	7.50 $ 	6.83
Cost of revenues adjustments (a) 	0.00 	0.05 	0.04 	0.15
Selling, general and administrative expenses adjustments (b) 	(0.17) 	0.01 	(0.12) 	0.03
Restructuring and other costs (c) 	0.20 	0.47 	0.28 	0.76
Amortization of acquisition-related intangible assets 	1.34 	1.51 	2.78 	3.07
Other income/expense adjustments (d) 	0.00 	0.00 	(0.03) 	0.11
Provision for income taxes adjustments (e) 	(0.26) 	(0.44) 	(0.13) 	(0.88)
Equity in earnings/losses of unconsolidated entities 	0.22 	0.04 	0.16 	0.11
Noncontrolling interests adjustments (f) 	0.00 	0.00 	0.00 	0.00
Adjusted EPS (non-GAAP measure) 	$ 	5.37 $ 	5.15 $ 	10.47 $ 	10.18
Reconciliation of free cash flow
GAAP net cash provided by operating activities 	$ 	1,960 $ 	1,540 $ 	3,211 $ 	2,269
Purchases of property, plant and equipment 	(301) 	(284) 	(648) 	(742)
Proceeds from sale of property, plant and equipment 	15 	4 	20 	10
Free cash flow (non-GAAP measure) 	$ 	1,674 $ 	1,260 $ 	2,583 $ 	1,537
(a) Adjusted results exclude charges for inventory write-downs associated with large-scale abandonment of product lines and accelerated depreciation on fixed assets to be abandoned
due to facility consolidations. Adjusted results in the second quarter and first six months of 2023 exclude $11 million and $21 million, respectively, of charges for the sale of
inventory revalued at the date of acquisition.
(b) Adjusted results exclude certain third-party expenses, principally transaction/integration costs related to recent acquisitions, and charges/credits for changes in estimates of
contingent acquisition consideration.
(c) Adjusted results exclude restructuring and other costs consisting principally of severance, impairments of long-lived assets, net charges for pre-acquisition litigation and other
matters, abandoned facilities, and other expenses of headcount reductions and real estate consolidations. Adjusted results in the second quarter of 2023 also exclude $26 million
of contract termination costs associated with facility closures.
(d) Adjusted results exclude net gains/losses on investments.
(e) Adjusted results in exclude incremental tax impacts for the reconciling items between GAAP and adjusted net income, incremental tax impacts as a result of tax rate/law changes,
and the tax impacts from audit settlements.
(f) Adjusted results exclude the incremental impacts for the reconciling items between GAAP and adjusted net income attributable to noncontrolling interests.
Critical Accounting Policies and Estimates
Management’s Discussion and Analysis and Note 1 to the Consolidated Financial Statements of the company’s Annual Report on Form 10-K for 2023 describe the
significant accounting estimates and policies used in preparation of the consolidated financial statements. There have been no significant changes in the company’s
critical accounting policies during the first six months of 2024.
Recent Accounting Pronouncements
A description of recently issued accounting standards is included under the heading “Recent Accounting Pronouncements” in Note 1.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
The company’s exposure to market risk from changes in interest rates and currency exchange rates has not changed materially from its exposure discussed in the
company’s Annual Report on Form 10-K for the year ended December 31, 2023.
Item 4. Controls and Procedures
Management’s Evaluation of Disclosure Controls and Procedures
The company’s management, with the participation of the company’s chief executive officer and chief financial officer, has evaluated the effectiveness of the
company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period
covered by this report. Management recognizes that any controls
31

-- 31 of 38 --

THERMO FISHER SCIENTIFIC INC.
and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily
applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on such evaluation, the company’s chief executive officer
and chief financial officer concluded that, as of the end of such period, the company’s disclosure controls and procedures were effective at the reasonable assurance
level.
Changes in Internal Control over Financial Reporting
There have been no changes in the company’s internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) during the fiscal
quarter ended June 29, 2024, that have materially affected or are reasonably likely to materially affect the company’s internal control over financial reporting.
PART II OTHER INFORMATION
Item 1. Legal Proceedings
There are various lawsuits and claims against the company involving product liability, intellectual property, employment and commercial issues. See Note 8 to our
Condensed Consolidated Financial Statements under the heading “Commitments and Contingencies.”
Item 1A. Risk Factors
The risks that we believe are material to our investors are discussed in the company’s Annual Report on Form 10-K for the year ended December 31, 2023 under the
caption “Risk Factors,” which is on file with the SEC.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Issuer Purchases of Equity Securities
There was no share repurchase activity for the company's second quarter of 2024. On November 14, 2023, the Board of Directors announced that it replaced the
existing authorization to repurchase the company’s common stock, of which $1.00 billion was remaining, with a new authorization to repurchase up to $4.00 billion
of the company’s common stock. At June 29, 2024, $1.00 billion was available for future repurchases of the company’s common stock under this authorization.
Item 5. Other Information
Director and Officer Trading Arrangements
None of our directors or officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of
Regulation S-K) during the quarterly period covered by this report.
32

-- 32 of 38 --

THERMO FISHER SCIENTIFIC INC.
Item 6. Exhibits
Exhibit
Number 	Description of Exhibit
31.1 	Certification of Chief Executive Officer required by Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of
2002.
31.2 	Certification of Chief Financial Officer required by Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of
2002.
32.1 	Certification of Chief Executive Officer required by Exchange Act Rules 13a-14(b) and 15d-14(b), as adopted pursuant to Section 906 of the Sarbanes-Oxley Act
of 2002.**
32.2 	Certification of Chief Financial Officer required by Exchange Act Rules 13a-14(b) and 15d-14(b), as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002.**
101.INS 	XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL
document.
101.SCH 	XBRL Taxonomy Extension Schema Document.
101.CAL 	XBRL Taxonomy Calculation Linkbase Document.
101.DEF 	XBRL Taxonomy Definition Linkbase Document.
101.LAB 	XBRL Taxonomy Label Linkbase Document.
101.PRE 	XBRL Taxonomy Presentation Linkbase Document.
104 	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
The Registrant agrees, pursuant to Item 601(b)(4)(iii)(A) of Regulation S-K, to furnish to the Commission, upon request, a copy of each instrument with respect to
long-term debt of the Registrant or its consolidated subsidiaries.
_______________________
** Certification is not deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section. Such certification is not deemed to be
incorporated by reference into any filing under the Securities Act or the Exchange Act except to the extent that the registrant specifically incorporates it by reference.
33

-- 33 of 38 --

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
Date: 	August 2, 2024 	THERMO FISHER SCIENTIFIC INC.
/s/ Stephen Williamson
Stephen Williamson
Senior Vice President and Chief Financial Officer
/s/ Joseph R. Holmes
Joseph R. Holmes
Vice President and Chief Accounting Officer
34

-- 34 of 38 --

Exhibit 31.1
THERMO FISHER SCIENTIFIC INC.
CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Marc N. Casper, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of Thermo Fisher Scientific Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and
have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that
material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to
provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal
quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s
auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to
adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over
financial reporting.
Date: August 2, 2024
/s/ Marc N. Casper
Marc N. Casper
Chairman, President and Chief Executive Officer

-- 35 of 38 --

Exhibit 31.2
THERMO FISHER SCIENTIFIC INC.
CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Stephen Williamson, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of Thermo Fisher Scientific Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and
have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that
material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to
provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal
quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s
auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to
adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over
financial reporting.
Date: August 2, 2024
/s/ Stephen Williamson
Stephen Williamson
Senior Vice President and Chief Financial Officer

-- 36 of 38 --

Exhibit 32.1
THERMO FISHER SCIENTIFIC INC.
CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(b) and 15d-14(b),
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Thermo Fisher Scientific Inc. (the “Company”) for the period ended June 29, 2024 as filed with the
Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Marc N. Casper, Chairman, President and Chief Executive Officer of the
Company, hereby certifies, pursuant to Securities Exchange Act of 1934 Rules 13a-14(b) and 15d-14(b), that:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: August 2, 2024
/s/ Marc N. Casper
Marc N. Casper
Chairman, President and Chief Executive Officer
A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that
appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Thermo Fisher Scientific Inc. and will be
retained by Thermo Fisher Scientific Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

-- 37 of 38 --

Exhibit 32.2
THERMO FISHER SCIENTIFIC INC.
CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(b) and 15d-14(b),
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Thermo Fisher Scientific Inc. (the “Company”) for the period ended June 29, 2024 as filed with the
Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Stephen Williamson, Senior Vice President and Chief Financial Officer of
the Company, hereby certifies, pursuant to Securities Exchange Act of 1934 Rules 13a-14(b) and 15d-14(b), that:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: August 2, 2024
/s/ Stephen Williamson
Stephen Williamson
Senior Vice President and Chief Financial Officer
A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that
appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Thermo Fisher Scientific Inc. and will be
retained by Thermo Fisher Scientific Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

-- 38 of 38 --